Brokers Set Expectations for TSE:BHC FY2024 Earnings

Bausch Health Companies Inc. (TSE:BHC) – Analysts at Zacks Research increased their FY2024 EPS estimates for Bausch Health Companies in a research note issued to investors on Tuesday, December 17th. Zacks Research analyst R. Department now anticipates that the company will post earnings of $5.33 per share for the year, up from their prior forecast of $5.21. The consensus estimate for Bausch Health Companies’ current full-year earnings is $5.55 per share. Zacks Research also issued estimates for Bausch Health Companies’ Q4 2024 earnings at $1.60 EPS, Q1 2025 earnings at $1.22 EPS, Q2 2025 earnings at $1.47 EPS, Q3 2025 earnings at $1.65 EPS, FY2025 earnings at $6.13 EPS, Q1 2026 earnings at $1.56 EPS, Q2 2026 earnings at $1.63 EPS, Q3 2026 earnings at $1.96 EPS and FY2026 earnings at $7.23 EPS.

Bausch Health Companies (TSE:BHC) last announced its earnings results on Wednesday, October 30th. The company reported C$1.53 EPS for the quarter, beating analysts’ consensus estimates of C$1.43 by C$0.10. Bausch Health Companies had a negative return on equity of 2,304.54% and a negative net margin of 5.12%. The business had revenue of C$3.42 billion during the quarter, compared to analysts’ expectations of C$3.36 billion.

Separately, Evercore ISI upgraded shares of Bausch Health Companies to a “hold” rating in a research report on Tuesday, October 15th.

Bausch Health Companies Trading Up 0.5 %

Shares of BHC stock opened at C$10.64 on Thursday. Bausch Health Companies has a fifty-two week low of C$5.45 and a fifty-two week high of C$15.43. The firm has a market capitalization of C$3.91 billion, a P/E ratio of -6.08, a PEG ratio of 0.21 and a beta of 0.77. The stock’s fifty day moving average is C$11.67 and its two-hundred day moving average is C$9.94. The company has a debt-to-equity ratio of 7,583.76, a quick ratio of 0.58 and a current ratio of 1.19.

About Bausch Health Companies

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.